IMPROVEMENT IN PATIENT SYMPTOMS AND FUNCTIONING DURING LONG-TERM TREATMENT WITH OLANZAPINE LONG-ACTING INJECTION (OLAI)

被引：0
|
作者：
Peuskens, J. [1 ]
Porsdal, V. [2 ]
Pecenak, J. [3 ]
Handest, P. [4 ]
D'yachkova, Y. [5 ]
Brousil, R. [6 ]
Casillas, M. [7 ]
Deberdt, W. [8 ]
机构：
[1] UPC KU Leuven, Kortenberg, Belgium
[2] Eli Lilly, Lyngby, Denmark
[3] Comenius Univ, Med Fac, Bratislava, Slovakia
[4] Psykiatrisk Ctr Hvidovre, Brondby, Denmark
[5] Eli Lilly, Vienna, Austria
[6] Eli Lilly, Prague, Czech Republic
[7] Eli Lilly, Alcobendas, Spain
[8] Eli Lilly & Co, Brussels, Belgium
来源：
EUROPEAN PSYCHIATRY | 2011年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
P03-303
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis
    Joseph Peuskens
    Vibeke Porsdal
    Jan Pecenak
    Peter Handest
    Yulia D'yachkova
    Radim Brousil
    Walter Deberdt
    [J]. BMC Psychiatry, 12
  • [2] Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis
    Peuskens, Joseph
    Porsdal, Vibeke
    Pecenak, Jan
    Handest, Peter
    D'yachkova, Yulia
    Brousil, Radim
    Deberdt, Walter
    [J]. BMC PSYCHIATRY, 2012, 12
  • [3] OLANZAPINE LONG-ACTING INJECTION FOR SCHIZOPHRENIA: AN EVALUATION OF PATIENT FUNCTIONING DURING 24 WEEKS OF MAINTENANCE THERAPY
    Novick, D.
    Anand, H.
    Ascher-Svanum, H.
    Haro, J.
    Bertsch, J.
    Cui, Z.
    Detke, H.
    Mcdonnell, D.
    Montgomery, W.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A287 - A287
  • [4] Hospitalization rates decrease during long-term treatment with long-acting risperidone injection
    Chue, P
    Devos, E
    Duchesne, I
    Leal, A
    Mehnert, A
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S281 - S282
  • [5] LONG-TERM FUNCTIONAL IMPROVEMENTS IN THE 2-YEAR TREATMENT OF SCHIZOPHRENIA OUTPATIENTS WITH OLANZAPINE LONG-ACTING INJECTION
    Ascher-Svanum, Haya
    Novick, Diego
    Haro, Josep M.
    Bertsch, Jordan
    McDonnell, David
    Detke, Holland
    [J]. SCHIZOPHRENIA RESEARCH, 2012, 136 : S165 - S165
  • [6] Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
    Ascher-Svanum, Haya
    Novick, Diego
    Maria Haro, Josep
    Bertsch, Jordan
    McDonnell, David
    Detke, Holland
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 1125 - 1131
  • [7] Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
    Citrome, Leslie
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2009, 3 : 345 - 355
  • [8] Olanzapine long-acting injection (OLAI) and post-injection delirium/sedation syndrome (PDSS): two case reports
    Gallo, Mariapina
    Ferri, Francesco
    Eleftheriou, Georgios
    Contessa, Maria Gioia
    Faraoni, Lorella
    Bacis, Giuseppe
    [J]. CLINICAL TOXICOLOGY, 2016, 54 (08) : 745 - 745
  • [9] Patient satisfaction and caregiver burden related to olanzapine long-acting injection
    Mcdonnell, D.
    Detke, H.
    Liu, C.
    Moore, K.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 125 - 126
  • [10] COST-EFFECTIVENESS ANALYSIS OF OLANZAPINE LONG-ACTING INJECTION COMPARED WITH RISPERIDONE LONG-ACTING INJECTION IN THE TREATMENT OF SCHIZOPHRENIA IN NORWAY
    Carroll, S. M.
    Jemiai, N.
    Suter, B.
    O'Donohoe, P.
    Skjoldborg, U.
    Moller, J.
    Kleivenes, O. K.
    Novick, D.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A358 - A358
12345